METHODS: Thirty triathletes were sampled monthly for 11 months. The samples were analyzed for human growth hormone (hGH), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), insulin, and N-terminal propeptide of type III procollagen (P-III-NP) by immunoassay. Bayesian and ANOVA methods were applied to estimate within-subject (CVI) and between-subject BV.
RESULTS: CVI estimates ranged from 7.8% for IGFBP-3 to 27.0% for insulin, when derived by the Bayesian method. The 2 models gave similar results, except for P-III-NP. Data were heterogeneously distributed for P-III-NP for the overall population and in females for IGF-1 and IGFBP-3. BV components were not estimated for hGH due to lack of steady state. The index of individuality was below 0.6 for all measurands, except for insulin.
CONCLUSIONS: In an athlete population, to apply a common CVI for insulin would be appropriate, but for IGF-1 and IGFBP-3 gender-specific estimates should be applied. P-III-NP data were heterogeneously distributed and using a mean CVI may not be representative for the population. The high degree of individuality for IGF-1, IGFBP-3, and P-III-NP makes them good candidates to be interpreted through reference change values and the ABP.
方法:每月抽取30名铁人三项运动员,共11个月。分析样品的人生长激素(hGH),胰岛素样生长因子-1(IGF-1),胰岛素样生长因子结合蛋白3(IGFBP-3),胰岛素,免疫测定III型前胶原的N端前肽(P-III-NP)。贝叶斯和ANOVA方法用于估计受试者内(CVI)和受试者间BV。
结果:CVI估计范围为IGFBP-3的7.8%至胰岛素的27.0%,当通过贝叶斯方法得出时。这两个模型给出了类似的结果,除了P-III-NP。P-III-NP的数据在总体人群中以及在女性中的IGF-1和IGFBP-3中分布不均。由于缺乏稳态,未估计hGH的BV成分。所有被测量的个性指数都低于0.6,除了胰岛素.
结论:在运动员群体中,对胰岛素应用普通CVI是合适的,但对于IGF-1和IGFBP-3,应采用性别特异性估计。P-III-NP数据是异质分布的,使用平均CVI可能不代表人群。IGF-1,IGFBP-3和P-III-NP的高度个性化使其成为通过参考变化值和ABP进行解释的良好候选者。